Posaconazole study for infants under 2 with serious fungal infection
Treatments studied
Part of Infections clinical trials.
This trial tests whether posaconazole, given through a vein or by mouth, can treat invasive fungal infections in children under 2 years old. It may help improve outcomes for infants with hard-to-treat fungal disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is being treated for a serious fungal infection (or the doctor thinks one is present)
- If in one part of the study, the infection is not invasive candidiasis (a specific yeast infection)
- Your child has a central line (a medical line in a large vein) now or planned before starting IV medicine
- Your child weighs at least 500 grams
- Posaconazole has not been given in the last 30 days
- Your child is expected to live at least 5 days and is stable enough to participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving the antifungal drug posaconazole as a tablet can prevent serious fungal infections in people who have had a stem cell transplant and develop gut graft-versus-host disease (GVHD), which is a complication where donor cells attack the digestive tract. It may help protect patients who need strong immune-suppressing treatment for GVHD.
This trial tests whether the antifungal drug posaconazole can prevent serious fungal infections in people who are at high risk after a stem cell transplant. If you qualify, you would take posaconazole during your recovery.
This study looks at how much posaconazole stays in your body while you receive it to prevent fungal infections during chemotherapy or after a stem cell transplant. Your care team will use standard posaconazole treatment and may take extra blood samples to understand its levels.
This study monitors how the antifungal drug isavuconazole works in children's bodies. It aims to find the right dose for treating serious fungal infections.
This study compares two antifungal medications (itraconazole and posaconazole) to see which works better for a chronic fungal lung infection called aspergillosis. If you have this condition, taking part may help control your symptoms and improve your quality of life.
This trial tests whether using a targeted antifungal medicine (aimed at PTX3) can better prevent serious fungal infections in adults with AML or a related bone marrow disease who will have very low neutrophils. It may help lower the risk of dangerous infections during intensive chemotherapy hospital stays.
Hear when a new Invasive Fungal Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.